ArticleRenal failure2025
The predictive value of suPAR for glomerular segmental sclerosis lesions in renal pathology.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Soluble Urokinase Plasminogen Activator Receptor (suPAR) Predicts 28-Day and 90-Day Mortality in Emergency Department Patients with Chest Pain, Dyspnoea, or Abdominal Pain.Diagnostics (Basel, Switzerland) · 2025Article
- Serum Factors in Primary Podocytopathies.Antibodies (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSoluble urokinase-type plasminogen activator receptor (suPAR) is a potential circulating pathogenic factor in idiopathic focal segmental glomerulosclerosis (iFSGS); however, its role remains controversial. Glomerular segmental sclerosis lesions (S lesions) are commonly observed in IgA nephropathy (IgAN). This study aims to investigate the correlation between suPAR and S lesions, particularly in IgAN, and to evaluate the potential of suPAR as a prognostic marker.
methodsPatients were selected from the Second Xiangya Hospital, including 47 cases of IgAN with S lesions (IgAN(S1 group)), 13 cases of IgAN without S lesions (IgAN(S0 group)), and 13 cases of iFSGS. Healthy control group of 20 individuals was selected. Serum suPAR concentration was measured, and its correlation with clinical and pathological data was analyzed. Patients were followed to evaluate the prognostic value of suPAR.
resultsCompared to the healthy control group and IgAN (S0 group), patients in the iFSGS and IgAN (S1 group) had significantly higher serum suPAR concentration (
conclusionsHigh serum suPAR concentration is a predictor of S lesions in the kidney and a risk factor for poor prognosis, making it a potential therapeutic target and prognostic predictor for kidney disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.